STOCK TITAN
  1. Home
  2. News
  3. NMRD

Nemaura Medical Inc - NMRD STOCK NEWS

Welcome to our dedicated news page for Nemaura Medical (Ticker: NMRD), a resource for investors and traders seeking the latest updates and insights on Nemaura Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nemaura Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nemaura Medical's position in the market.

News
Important Update on Listing Status and Strategic Direction
Rhea-AI Summary
Nemaura Medical Inc. (NMRD) to Move from Nasdaq to OTC Markets: Strategic Decision and Future Outlook
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.91%
Tags
none
-
News
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
Rhea-AI Summary
Nemaura Medical Inc. (NASDAQ: NMRD) has been granted continued listing on The Nasdaq Capital Market until April 1st, 2024, by the Nasdaq Hearings Panel. The company is focused on developing a non-invasive glucose sensor and digital healthcare programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.57%
Tags
none
-
News
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
Rhea-AI Summary
Nemaura Medical Inc. (NMRD) secures a $10 million credit facility to support strategic growth plans, minimizing dilution and preserving shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.93%
Tags
none
News
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
Rhea-AI Summary
Nemaura Medical: UK Launches Groundbreaking Metabolic Health and Weight Management Program Integrating Continuous Glucose Monitoring and GLP-1 Agonists
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
-
News
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
Rhea-AI Summary
Nemaura Medical, Inc. (Nasdaq: NMRD) released its financial results for the quarter ended September 30, 2023, and provided a business update. The company continued to support its UK licensee for sensor reimbursement, advanced development of BEATdiabetes, and received approval for marketing sugarBEAT in Saudi Arabia. Financially, R&D expenses increased, while net loss decreased, with cash and cash equivalents at approximately $4.4m.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
earnings
-
News
Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.
Rhea-AI Summary
Nemaura Medical appoints Nikolai Rozanov as strategic adviser in AI development, solidifying the company's expertise in the growing AI sector. This will allow for the integration of data from its CGM to create tailored programs and personalized recommendations. AI-based models have a vital role in the healthcare and lifestyle sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
management AI
News
Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference
Rhea-AI Summary
Nemaura Medical CEO to present business updates at Maxim Group conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
conferences acquisition
-
News
Nemaura Medical Provides Update on Nasdaq Compliance Status and Process
Rhea-AI Summary
Nemaura Medical, Inc. provides update on compliance with Nasdaq listing standards, anticipates delisting determination after grace periods expire. Company plans to request a hearing before a Nasdaq Hearings Panel for possible extension. Continues to focus on business expansion and product launch in Saudi Arabia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
none
-
News
Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program
Rhea-AI Summary
Nemaura Medical announces interim results from its metabolic health program, showing weight loss of 2.9KG on average after 20 weeks. Retention rate of 32.5% and 64% of active participants likely to continue the program. Company plans to offer low-cost CGM-embedded program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.86%
Tags
none
News
Nemaura Medical Announces Participation at HLTH 2023, Las Vegas
Rhea-AI Summary
Nemaura Medical to participate at HLTH 2023 conference, showcasing their wearable diagnostic device and diabetes management program integration
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
none
Stock NMRD logo
Nemaura Medical Inc

Nasdaq:NMRD

NMRD Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NMRD Stock Data

2.46M
14.84M
48.62%
4.41%
0.18%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
New York

About NMRD

nemaura medical inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. the company provides sugarbeat, a non-invasive continuous glucose monitoring device for use by persons with type i and type ii diabetes, as well as for screening pre-diabetic patients. it has a license agreement with healthimation, llc, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for type 2 diabetes, prediabetes, and general wellness; the why wait app; and common law trademarks which incorporate the mark why wait or whywait and the use of licensed marks. nemaura medical inc. was founded in 2009 and is based in new york, new york.